High-yield overview
Blood Conservation in Orthopaedic Surgery
3 pillarsRed cell mass / blood loss / tolerance
TXACornerstone antifibrinolytic
RestrictiveTransfuse ~70-80 g/L or symptoms
Cell salvageLimited added benefit over TXA (primary)
The three pillars of patient blood management
1. Optimise red cell mass
PatternScreen and treat PRE-OPERATIVE ANAEMIA - iron (oral/IV), B12/folate, and erythropoietin in selected patients - before elective surgery.
Treatment
2. Minimise blood loss
PatternMeticulous surgical haemostasis, TRANEXAMIC ACID, regional/hypotensive anaesthesia, tourniquet where appropriate, CELL SALVAGE, and managing anticoagulants.
Treatment
3. Optimise tolerance of anaemia
PatternRESTRICTIVE transfusion thresholds, single-unit transfusion with reassessment, and managing comorbidity (cardiorespiratory).
Treatment
Critical Must-Knows
- Patient Blood Management (PBM) is an evidence-based, patient-centred strategy built on THREE PILLARS: (1) OPTIMISE the patient's RED CELL MASS (treat pre-operative anaemia), (2) MINIMISE blood LOSS and bleeding, and (3) OPTIMISE the patient's physiological TOLERANCE of anaemia (restrictive transfusion) - the aim being to avoid or reduce ALLOGENEIC (donor) blood transfusion and its risks.
- TRANEXAMIC ACID (TXA) is the CORNERSTONE pharmacological measure: an antifibrinolytic (a lysine analogue that inhibits plasminogen activation) given intravenously or topically, it significantly REDUCES blood loss and the need for transfusion in arthroplasty, hip-fracture and trauma surgery WITHOUT a significant increase in thromboembolic events in trials.
- A RESTRICTIVE transfusion strategy - transfusing at a haemoglobin around 70-80 g/L (the higher end, ~80, in symptomatic or cardiovascular patients) or for symptoms of anaemia, rather than a 'liberal' trigger - is as safe as liberal transfusion and reduces unnecessary transfusion; transfuse SINGLE UNITS and REASSESS rather than giving fixed multi-unit orders.
- INTRAOPERATIVE CELL SALVAGE (collecting, washing and re-infusing the patient's own red cells) is useful in HIGH-BLOOD-LOSS surgery (revision arthroplasty, complex spine, pelvic/acetabular trauma), but in PRIMARY arthroplasty it adds LITTLE benefit OVER tranexamic acid alone and adds cost - so it is targeted to high-loss cases, not used routinely when TXA suffices; it is used cautiously in malignancy/infection.
- PRE-OPERATIVE ANAEMIA is a common, MODIFIABLE risk factor for transfusion and worse outcomes - elective patients should be screened and treated (iron deficiency with oral or IV iron, B12/folate, erythropoietin in selected cases) before surgery to build up red cell mass.
- JEHOVAH'S WITNESS patients DECLINE allogeneic blood (and usually pre-stored autologous blood) on religious grounds but, individually, often ACCEPT CELL SALVAGE and some fractionated products kept in CONTINUITY with their circulation; they require careful pre-operative PLANNING and documented consent/advance directive, maximisation of red cell mass (iron/erythropoietin), meticulous haemostasis, TXA, continuous-circuit cell salvage, a lower transfusion trigger, senior involvement and RESPECT for their autonomy.
Clinical Pearls
- “PBM 3 pillars: optimise red cell mass (treat anaemia), minimise blood loss (TXA/haemostasis/cell salvage), optimise anaemia tolerance (restrictive transfusion).
- “Tranexamic acid = cornerstone (reduces transfusion, no significant VTE increase). Restrictive trigger ~70-80 g/L; single-unit transfusion + reassess.
- “Cell salvage for HIGH-loss surgery (revision/spine/pelvis), limited added benefit over TXA in primary arthroplasty. Jehovah's Witness: plan ahead, document consent, accept cell salvage in continuity, respect autonomy.
Two Cornerstones: TXA and a Restrictive Trigger
Tranexamic acid
Antifibrinolytic that reduces blood loss and transfusion in arthroplasty/hip-fracture/trauma, with no significant rise in VTE - give IV and/or topical to most major orthopaedic cases.
Restrictive transfusion
Transfuse at ~70-80 g/L (or for symptoms), single units with reassessment - as safe as a liberal trigger and avoids unnecessary transfusion.
The Three Pillars
Optimise, Minimise, Tolerate
PBM reframes care around the patient's own blood rather than the blood bank. Pillar 1 - optimise red cell mass: screen for and treat pre-operative anaemia (iron, B12/folate, erythropoietin in selected cases) before elective surgery. Pillar 2 - minimise blood loss: meticulous surgical haemostasis, tranexamic acid, regional/hypotensive anaesthesia, a tourniquet where appropriate, cell salvage in high-loss cases, and careful management of anticoagulants/antiplatelets. Pillar 3 - optimise tolerance of anaemia: a restrictive transfusion threshold, single-unit transfusion with reassessment, and managing cardiorespiratory comorbidity. Together these reduce exposure to allogeneic blood and its risks (infection, TRALI, TACO, immunomodulation, cost).
Key Measures
TXA, Restrictive Transfusion and Targeted Cell Salvage
- Tranexamic acid: the most effective single pharmacological measure - reduces blood loss and the need for transfusion across arthroplasty, hip-fracture and trauma surgery, given IV and/or topically, without a significant increase in venous thromboembolism in trials.
- Restrictive transfusion: transfuse at a haemoglobin of about 70-80 g/L (using ~80 in symptomatic or cardiovascular patients) or for symptoms; give single units and reassess.
- Pre-operative anaemia optimisation: screen elective patients; treat iron deficiency (oral or IV iron), B12/folate, and use erythropoietin in selected cases.
- Cell salvage: reserve for high-blood-loss surgery (revision arthroplasty, complex spine, pelvic/ acetabular trauma); in primary arthroplasty it adds little over TXA alone and adds cost; use with caution in malignancy/infection.
- Anaesthetic/surgical adjuncts: regional or hypotensive anaesthesia, tourniquet, warming (hypothermia worsens coagulopathy), and managing anticoagulants/antiplatelets around surgery.
The Jehovah's Witness Patient
Jehovah's Witness patients decline allogeneic blood and usually pre-stored autologous blood, but individually many ACCEPT intraoperative cell salvage and some fractionated products provided these are kept in CONTINUITY with their circulation - so each patient's specific wishes must be clarified and documented. Plan ahead: an explicit advance directive/consent discussion, maximise red cell mass (iron and erythropoietin pre-operatively), meticulous haemostasis, tranexamic acid, continuous-circuit cell salvage, a lower transfusion trigger, senior anaesthetic and surgical involvement, and clear documentation. Above all, respect the patient's autonomy - their informed refusal must be honoured even if it risks life.
Evidence & Key Studies
Evidence
Interventions for reducing red blood cell transfusion in hip fracture surgery: an overview of systematic reviews
Lewis SR, Pritchard MW, Estcourt LJ, Stanworth SJ, Griffin XL • Cochrane Database of Systematic Reviews (2023)
Key Findings:
- Tranexamic acid probably reduces the need for allogeneic transfusion in hip-fracture surgery (risk ratio 0.56; about 194 fewer people per 1000 requiring transfusion) and reduces the volume transfused.
- There was probably little or no difference in adverse events (DVT, PE, MI, stroke, death) with tranexamic acid.
- Intravenous iron showed little or no overall difference, and evidence for other interventions was lacking - highlighting tranexamic acid as the best-supported measure.
Evidence
Combined intraoperative cell salvage and tranexamic acid for primary total hip arthroplasty: added benefit?
Miller TM, Fang C, Hagar A, et al. • Journal of Orthopaedic Science (2020)
Key Findings:
- In 1171 primary THAs, adding intraoperative cell salvage to tranexamic acid did NOT improve blood loss or transfusion outcomes compared with tranexamic acid alone.
- Cell salvage added about $146 per case (over $123,000 across the study period) with no observed clinical benefit.
- Routine cell salvage may not be justifiable in primary THA when tranexamic acid is used - reserve it for high-loss cases.
Evidence Attribution
According to PubMed, the efficacy of tranexamic acid in reducing transfusion (with little/no increase in adverse events) and the limited evidence for iron/other measures come from the cited Lewis Cochrane overview, and the lack of added benefit (and added cost) of cell salvage over tranexamic acid alone in primary THA from the cited Miller study. The three-pillar PBM framework, restrictive transfusion thresholds and Jehovah's Witness planning are standard, well-established perioperative teaching. (See also our Preoperative Optimisation, Venous Thromboembolism Prophylaxis and Anaemia topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
Viva scenarioStandard
Clinical prompt
“How would you minimise blood transfusion in a patient undergoing major joint arthroplasty?”
Practical approach
I would use a patient blood management approach built on three pillars. First, optimise the patient's red cell mass before surgery by screening for and treating pre-operative anaemia, most commonly iron deficiency with oral or intravenous iron, correcting B12 or folate deficiency, and using erythropoietin in selected patients, because pre-operative anaemia is a common and modifiable risk factor for transfusion and worse outcomes. Second, minimise blood loss intra-operatively and peri-operatively: meticulous surgical haemostasis, tranexamic acid, which is the cornerstone antifibrinolytic and reduces blood loss and transfusion without a significant increase in thromboembolism, given intravenously and or topically, regional or hypotensive anaesthesia, a tourniquet where appropriate, careful management of anticoagulants and antiplatelets, keeping the patient warm, and intraoperative cell salvage in high-loss cases. Third, optimise the patient's tolerance of anaemia by using a restrictive transfusion threshold, transfusing at a haemoglobin of about seventy to eighty grams per litre or for symptoms rather than a liberal trigger, giving single units and reassessing, and managing cardiorespiratory comorbidity. I would note that in primary arthroplasty, cell salvage adds little over tranexamic acid alone and adds cost, so I would reserve it for high-blood-loss procedures such as revision arthroplasty, complex spine or pelvic trauma.
Key clinical points
Three pillars: optimise red cell mass (treat anaemia), minimise blood loss, optimise anaemia tolerance
Tranexamic acid is the cornerstone (reduces transfusion, no significant VTE increase)
Restrictive transfusion (~70-80 g/L or symptoms), single-unit transfusion + reassess
Cell salvage for high-loss cases (revision/spine/pelvis); limited added benefit over TXA in primary arthroplasty
Common pitfalls
Ignoring/ not treating pre-op anaemia
Routine cell salvage in primary arthroplasty (cost, little added benefit over TXA)
Liberal multi-unit transfusion instead of restrictive single-unit-and-reassess
Further questions
“What is the cornerstone pharmacological measure? - Tranexamic acid”
“What restrictive transfusion threshold? - About 70-80 g/L (or symptoms)”
Viva scenarioStandard
Clinical prompt
“How would you plan surgery for a Jehovah's Witness patient who needs a high-blood-loss operation and declines allogeneic blood?”
Practical approach
The guiding principle is respect for the patient's autonomy, so their informed refusal of allogeneic blood must be honoured even if it risks their life, and I would manage them through careful, proactive planning. First I would have an early, explicit discussion to clarify and document exactly what they will and will not accept, because individual Jehovah's Witnesses differ: they decline allogeneic and usually pre-stored autologous blood, but many will accept intraoperative cell salvage and certain fractionated products if these are kept in continuity with their circulation, so I would record this in a consent form and advance directive with senior involvement. Then I would apply all three pillars of blood management aggressively. Pre-operatively I would maximise red cell mass by treating anaemia with iron and erythropoietin and allowing time for the haemoglobin to rise. Intra-operatively I would minimise blood loss with meticulous haemostasis, tranexamic acid, regional or hypotensive anaesthesia, careful positioning, warming, and continuous-circuit cell salvage if the patient accepts it. Post-operatively I would tolerate a lower haemoglobin with a lower transfusion trigger that respects their wishes, optimise oxygen delivery, continue iron and erythropoietin, and minimise blood sampling. I would involve a consultant anaesthetist, a consultant surgeon, and the hospital's transfusion or bloodless-surgery team, and ensure the plan is clearly communicated to the whole team.
Key clinical points
Respect autonomy: honour informed refusal; clarify and DOCUMENT exactly what is/isn't accepted (varies individually)
Many accept cell salvage / fractionated products kept in CONTINUITY with circulation; decline allogeneic + stored autologous
Maximise red cell mass pre-op (iron + erythropoietin, allow time)
Intra-op: haemostasis, TXA, hypotensive/regional anaesthesia, continuous-circuit cell salvage; post-op lower trigger, minimise sampling; senior MDT involvement
Common pitfalls
Not clarifying/documenting the patient's specific wishes in advance
Assuming all products are refused (cell salvage in continuity often accepted)
Failing to optimise red cell mass and haemostasis proactively
Further questions
“What do most Jehovah's Witnesses accept? - Cell salvage / some fractions in continuity with the circulation (individualised)”
“Key pre-op measure to raise haemoglobin? - Iron + erythropoietin (with time)”
Mnemonics & Memory Aids
Mnemonic
3 PILLARS
1
Optimise red cell mass (treat pre-op anaemia: iron/B12/folate/EPO)
2
Minimise blood loss (haemostasis, TXA, cell salvage, manage anticoagulants)
3
Optimise anaemia tolerance (restrictive transfusion, single-unit, treat comorbidity)
Hook:PBM = optimise red cell mass, minimise loss, tolerate anaemia.
Mnemonic
SAVE BLOOD
S
Single-unit transfusion + reassess
A
Antifibrinolytic - tranexamic acid (cornerstone)
V
Volume loss minimised (haemostasis, hypotensive anaesthesia, tourniquet)
E
Erythropoietin/iron - treat pre-op anaemia
B
Blood salvage (cell salvage) for high-loss cases
L
Lower (restrictive) transfusion trigger ~70-80 g/L
OOD
Observe patient wishes (Jehovah's Witness - document, respect autonomy)
Hook:SAVE BLOOD captures the blood-conservation toolkit.
Exam day cheat sheet
Patient Blood Management - Exam Day Cheat Sheet
Three pillars
- Optimise red cell mass: treat pre-op anaemia (iron/B12/folate, EPO selected)
- Minimise blood loss: haemostasis, TXA, cell salvage, manage anticoagulants
- Optimise anaemia tolerance: restrictive transfusion, single-unit + reassess
Tranexamic acid
- Antifibrinolytic (lysine analogue); IV and/or topical
- Reduces blood loss + transfusion (arthroplasty/hip fracture/trauma)
- No significant increase in VTE in trials - cornerstone measure
Transfusion & cell salvage
- Restrictive trigger ~70-80 g/L (or symptoms); single units + reassess
- Cell salvage for high-loss cases (revision/spine/pelvis)
- Cell salvage adds little over TXA in PRIMARY arthroplasty (cost)
Jehovah's Witness
- Decline allogeneic + stored autologous blood; respect autonomy
- Often accept cell salvage/fractions in CONTINUITY with circulation (individualise + document)
- Maximise red cell mass (iron/EPO), TXA, haemostasis, lower trigger, senior MDT